U.S., July 18 -- ClinicalTrials.gov registry received information related to the study (NCT07070128) titled 'Screening Tool Artificial Intelligence-based for Predicting the Genetic Risk of BREAST Cancer' on April 16.
Brief Summary: It is a retrospective observational study that will include female patients aged 18 years or older, who were treated between 2017 and 2024, in both public and private institutions, and identified as at high genetic risk by breast specialists and referred to a geneticist. The artificial intelligence-based tool to be used in this study is developed by the startup WeConecta, which will collect data via WhatsApp about the patients' family cancer history with the aim of predicting the genetic risk of developing breas...